Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) had its price target raised by investment analysts at Citigroup Inc. from $154.00 to $155.00 in a research note issued on Tuesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup Inc.’s price target suggests a potential upside of 18.16% from the company’s previous close.

ALXN has been the subject of several other research reports. Vetr downgraded shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $171.50 target price for the company. in a research report on Thursday, June 2nd. Leerink Swann reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, June 7th. Brean Capital reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, June 7th. Morgan Stanley reissued an “overweight” rating and issued a $189.00 target price (down previously from $203.00) on shares of Alexion Pharmaceuticals in a research report on Tuesday, June 7th. Finally, Oppenheimer Holdings Inc. reissued a “buy” rating and issued a $221.00 target price (down previously from $228.00) on shares of Alexion Pharmaceuticals in a research report on Tuesday, June 7th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $182.85.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 131.18 on Tuesday. The company has a 50-day moving average of $131.30 and a 200-day moving average of $135.95. The firm has a market cap of $29.42 billion, a P/E ratio of 329.60 and a beta of 1.08. Alexion Pharmaceuticals has a 12 month low of $110.56 and a 12 month high of $193.45.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/alexion-pharmaceuticals-inc-alxn-given-new-155-00-price-target-at-citigroup-inc.html

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $1.13 EPS for the quarter, missing analysts’ consensus estimates of $1.17 by $0.04. Alexion Pharmaceuticals had a return on equity of 10.02% and a net margin of 3.19%. The firm earned $753 million during the quarter, compared to analyst estimates of $743.18 million. During the same quarter in the prior year, the firm earned $1.44 EPS. The business’s quarterly revenue was up 18.4% compared to the same quarter last year. Equities analysts forecast that Alexion Pharmaceuticals will post $4.65 EPS for the current fiscal year.

In other news, Director Leonard Bell sold 1,010 shares of the business’s stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $137.14, for a total transaction of $138,511.40. Following the sale, the director now owns 405,289 shares in the company, valued at $55,581,333.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Vikas Sinha sold 277 shares of the business’s stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $137.14, for a total transaction of $37,987.78. Following the sale, the chief financial officer now owns 178,463 shares in the company, valued at approximately $24,474,415.82. The disclosure for this sale can be found here. Insiders own 4.41% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Investors Capital Advisory Services raised its stake in Alexion Pharmaceuticals by 0.7% in the second quarter. Investors Capital Advisory Services now owns 1,996 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 14 shares in the last quarter. Navellier & Associates Inc raised its position in Alexion Pharmaceuticals by 0.5% in the second quarter. Navellier & Associates Inc now owns 3,477 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 17 shares in the last quarter. Raymond James Trust N.A. raised its position in Alexion Pharmaceuticals by 0.9% in the first quarter. Raymond James Trust N.A. now owns 3,625 shares of the biopharmaceutical company’s stock valued at $505,000 after buying an additional 32 shares in the last quarter. Mn Services Vermogensbeheer B.V. raised its position in Alexion Pharmaceuticals by 0.8% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 5,691 shares of the biopharmaceutical company’s stock valued at $598,000 after buying an additional 43 shares in the last quarter. Finally, Rathbone Brothers plc raised its position in Alexion Pharmaceuticals by 2.7% in the second quarter. Rathbone Brothers plc now owns 1,890 shares of the biopharmaceutical company’s stock valued at $221,000 after buying an additional 50 shares in the last quarter. Institutional investors and hedge funds own 96.38% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.